Oramed Pharmaceuticals
ORMP
64 hedge funds and large institutions have $45M invested in Oramed Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
21% more capital invested
Capital invested by funds: $37.2M → $45M (+$7.8M)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
12% more funds holding
Funds holding: 57 → 64 (+7)
0.07% less ownership
Funds ownership: 32.81% → 32.74% (-0.07%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mercer Global Advisors
Denver,
Colorado
|
+$6.48M |
| 2 |
RWM
Ritholtz Wealth Management
New York
|
+$527K |
| 3 |
AF
Aquamarine Financial
George Town,
|
+$472K |
| 4 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$395K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIA
Gem Investment Advisors
Teaneck,
New Jersey
|
-$1.22M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$330K |
| 3 |
Squarepoint
New York
|
-$166K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
-$122K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$119K |
ORMP Hedge Fund Activity: Q1 2026 in Review
64 of the 8,198 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2026, worth a combined $45M — up 21% from $37.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ORMP positions and 8 closed out — a net gain of 8 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Mercer Global Advisors, opening a new position worth an estimated $6.48M. The largest seller was Gem Investment Advisors, cutting an estimated $1.22M.
- 64 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2026, up from 57 in Q4 2025.
- Funds reported $45M of Oramed Pharmaceuticals stock for Q1 2026, up 21% quarter-over-quarter.
- 16 funds opened new Oramed Pharmaceuticals positions in Q1 2026 and 8 closed out, a net change of +8 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2026 was Mercer Global Advisors, an estimated $6.48M added.
- The largest Oramed Pharmaceuticals seller in Q1 2026 was Gem Investment Advisors, an estimated $1.22M sold.
Based on aggregated 13F filings for Q1 2026.